arrow_back Back Filing freshness 10-Q Q3 FY2026 SEC EDGAR

Indivior Pharmaceuticals, Inc.

INDV
$36.26 0.00 (0.00%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
20 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
42
Health
Weak
Moderately Bullish
auto_awesome

Analytical Summary

Indivior Pharmaceuticals, Inc. shows strong fundamentals with top-quartile Profit Margin (%) and Debt to Equity. However, watch Return on Common Equity (%) which shows concerning trends. Overall, the data suggests a moderately positive outlook with manageable risks.

Market Cap $4.3B
Dividend Yield —
Revenue Growth 13.4% →
Op. Margin 50.6% ↗
ROIC -225.8% ↘
FCF / Share $0.70 ↘
Trailing P/E 31.3x
Price / Book —
FCF Yield 1.9%
Debt / Equity 0.00
info Valuation on last close. End-of-day price, Nov 2, 2026.

20-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$356.00M
↑ +13.4% —
Net Income Profit after all expenses
$89.00M
↑ +89.4% —
Operating Margin Operating profit as % of sales
50.6%
↑ +8.4% 77th
FCF / Share Free cash flow per share
$0.70
↓ -62.3% —
Long-Term Debt Long-term obligations
$0.00
↓ -100.0% —
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Profit Margin (%)Profit Margin (%) is in the top quartile
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↓
56
Returns
2
Financial Health ↓
89
Cash Quality
14

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 5 years · 20 quarters